Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. (2019). Swiss Medical Weekly, 149(5152), w20170. https://doi.org/10.4414/smw.2019.20170